Tuesday, 16 Jul 2019

You are here

Factors That Contribute to Uveitis in SpA

We know that uveitis is an extra-articular manifestation of SpA but what remains unclear is if there are any factors that may play a role in the development of uveitis. One group sought to understand these issues.

Dr. Kasifoglu et al sought to understand possible risk factors by looking at age, gender, duration of illness, BMI, educational status, smoking habits, SpA clinical findings and co-morbid disease, HLA B27 status, acute phase responses, VAS pain, VAS global, VAS fatigue, BASDAI and BASFI scores, swollen and tender joint counts and XR findings retrospectively.

The study looked at a total of 2359 SpA patients (2096 with axSPA, 1249 with AS, 100 with nr-axSpA, 179 with PsA, 50 with peripheral SPA and 51 with enteropathic arthritis.) Overall, 269 (11.4%) patients had experienced one or more episodes of uveitis. The median age of uveitis was 36 year old, with the start of SpA symptoms 6.8 years prior to uveitis. The median number of “attacks” was 2 (1-4) and were typically unilateral (78.9%.)   19/184 (10.3%) patients had permanent damage to the eye. These patients had more frequent attacks and had a tendency for bilateral eye involvement.

 

It appears that genetic background, radiographic severity of disease, presence of enthesis, and particularly disease duration may be related with uveitis. Although uveitis is usually self-limited, almost 10% of SpA patients may have permanent eye damage.

Add new comment

More Like This

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.

Recommendations for Exercise in Ankylosing Spondylitis

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

Biologic Retention in Ankylosing Spondylitis Patients

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

A nationwide Swedish Rheumatology register followed 2590 Bio-naïve AS who started a TNFi between 2006–2015.

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.